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Abstract
Background: This article aims to explain the reasons for the remarkable change in age of breast
cancer occurrence in the Swiss canton of Geneva.
Methods:  We used population-based data from the Geneva cancer registry, which collects
information on method of detection, stage and tumour characteristics since 1975. For patients
diagnosed between 1997–2003, we obtained additional information on use of hormone
replacement therapy from a large prospective study on breast cancer. Using generalized log linear
regression analysis, we compared age-specific incidence rates with respect to period, stage,
oestrogen receptor status, method of detection and use of hormone replacement therapy.
Results: In the periods 1975–1979 and 1985–1989, breast cancer risk increased with age, showing
the highest incidence rates among women aged ≥ 85 years. From 1997, the age-specific incidence
curve changed completely (p < 0.0001), showing an incidence peak at 60–64 years and a reduced
incidence among elderly women. This incidence peak concerned mainly early stage and oestrogen
positive cancers and was exclusively observed among women who ever used hormone
replacement therapy, regardless whether the tumour was screen-detected or not.
Conclusion: The increasing prevalence of hormone replacement therapy use during the 1990s
could explain the important change in age-specific breast cancer incidence, not only by increasing
breast cancer risk, but also by revealing breast cancer at an earlier age.
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Background
In Western countries, breast cancer is the most frequent
cancer among women and its incidence is still increasing.
Several factors have contributed to this increase. Screening
mammography temporarily increases incidence by dis-
covering incident, as well as prevalent cases. Higher expo-
sure to breast cancer risk factors, such as low and late
parity, alcohol intake and use of hormone replacement
therapy (HRT) [1,2] could also explain the incidence
increase. It has now been established that HRT represents
a true risk factor for breast cancer [3,4]. After the publica-
tion of the Women's Health Initiative in 2002, a study
reporting greater harm than benefit of HRT use [5], HRT
use has decreased sharply in Europe and North America
[6,7].
The Swiss canton of Geneva has one of the highest inci-
dence rates of breast cancer in the world [8]. Opportunis-
tic mammography screening was started in Geneva at the
end of the 1980's and in 1999 an organised mammogra-
phy screening program was implemented. This program
invites all resident women aged from 50 to 69 years every
two years to a free mammography with double reading.
However, the participation in the organised screening
program is low and most women undergo opportunistic
screening. The Swiss national Health Survey, performed in
1997, reported that 66% of the Geneva women aged ≥40
years had undergone at least one mammography exami-
nation [9].
Use of HRT was very common in Geneva where over 50%
of women aged 45–59 years used HRT in 1996 [10].
In this study, we describe changes in age-specific breast
cancer incidence in Geneva and examine possible reasons
for these changes.
Methods
We used data from the Geneva cancer registry, which
records information on all incident cancer cases that occur
in the canton (approximately 420,000 inhabitants). The
registration is based on several sources of information and
is very accurate, as attested by its low percentage (<2%) of
cases recorded from death certificates only [8]. All hospi-
tals and pathology laboratories report information on
every current and past cancer case to the Geneva cancer
registry. Trained tumour registrars systematically abstract
missing information and the cancer registry regularly
sends special questionnaires to private physicians to
secure information on patients treated in the private sec-
tor.
For every cancer case, we record sociodemographic char-
acteristics, method of detection of the tumour, tumour
characteristics, stage of disease at diagnosis, treatment,
survival status, and cause of death.
The study included all 8045 invasive breast cancer cases
diagnosed between 1975–2003 among the resident pop-
ulation. Method of detection was categorized as mam-
mography screening vs. other. Stage at diagnosis was
based on the Tumour, Node and Metastasis TNM classifi-
cation system [11]. Stages were classified into three
groups: stage I (T0 or T1, N0), stage II (T0 or T1 and N1,
T2 and N0 or N1, T3 and N0), and other stages (T0 or T1
or T2 and N2, T3 and N1 or N2, T4 and any N, any T and
N3, or M1, and unknown stages). Oestrogen receptor sta-
tus was categorized as positive if tumours presented oes-
trogen receptors in ≥ 10% of the tumour cells.
Additional information on the patient's use of hormone
replacement therapy (coded as ever vs. never user) was
provided by a large study on risk factors for breast cancer
[12]. This study was prospectively collected, by means of
personal interviews, information on life style factors of
breast cancer patients and control individuals.
This study included 400 breast cancer patients aged 50–74
years, diagnosed between 1997–2000 in the canton of
Geneva and they were individually linked to the cancer
registry data set. These women represented 46% of all
breast cancer patients in this age group recorded at the
cancer registry during the same period.
We calculated age-specific breast cancer incidence rates
per 100'000 by five-year age groups for four different peri-
ods (1975–1979, 1985–1989, 1997–2000, and 2001–
2003). Differences between age-specific incidence curves
were analyzed by generalized log linear regression analy-
sis [13]. We compared age-specific incidence rates among
the 400 patients with information on use of HRT dividing
them into four groups of patients: 1) ever used HRT,
tumour detected by mammography screening (n = 87), 2)
ever used HRT, tumour not detected by mammography
screening (n = 141), 3) never used HRT, tumour detected
by mammography screening (n = 53), 4) never used HRT,
tumour not detected by mammography screening (n =
119).
Results
Figure 1 shows the change in breast cancer incidence by
age. In the periods 1975–1979 and 1985–1989, breast
cancer incidence increased with age. Rates among women
aged ≥85 years (568/100'000) were at least three times
higher than among women aged 50–54 years (182/
1000'000). For the period 1997–2000, the age-specific
incidence curve was completely different and showed a
peak at 60–64 years (488/100'000). In this period, rates
among the oldest women (313/100'000) were muchBMC Cancer 2006, 6:78 http://www.biomedcentral.com/1471-2407/6/78
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lower and comparable to those of women aged 50–54
years (303/100'000). Data from the last available period
(2001–2003) confirmed the change in incidence rate by
age. The incidence peak among women aged 60–64 years,
occurring since 1997, involved mainly early stages (stage
I and II) and oestrogen receptor positive tumours (Figure
2). Table I compares the patient and tumour characteris-
tics among women aged 60–64 years before and after the
change in age-specific incidence. The proportion of stage I
disease rose from 32 to 48% (p < 0.001). Also, the propor-
tion of women of high social class was much higher in the
recent years. The proportion of lobular cancer increased
sharply: before the change in incidence pattern, lobular
cancer represented only 2% of the tumours occurring in
women aged 60–64 years, while afterwards, 14% of
women aged 60–64 years presented with lobular histol-
ogy.
Figure 3 presents incidence rates by age according to the
use of HRT and the method of tumour detection among
the 400 patients (aged 50–74 years) with available data
on HRT. As information on HRT use was available for
46% of all breast cancer patients, rates were approxi-
mately 50% of the overall breast cancer incidence rates for
the period 1997–2000. The age-specific incidence curves
were significantly different among ever users of HRT com-
pared with never users (P < 0.0001). The incidence peak
was observed only among ever users of HRT, regardless
whether the tumour was detected by mammography
screening or not. For women who never used HRT, there
was no incidence peak at 60–64 years.
Discussion
This study shows a remarkable change in age-specific
breast cancer incidence in Geneva. In developed coun-
tries, other than Japan, the typical age incidence curve of
breast cancer described a progressive increase of risk with
age, with a slope down around the menopause age, called
the Clemmensen's hook. This typical curve by age is no
longer observed in Geneva, where the risk of developing
breast cancer does not increase with advancing age any-
more. The highest breast cancer risk is now observed
among women aged 60–64 years with strongly decreased
risks among older women. The incidence peak of women
aged 60–64 years was only observed in early stage disease
and in oestrogen receptor positive tumours. In the sub-
group of women for whom information on HRT use and
mammography screening was available, the incidence
peak was only present among women who ever used HRT.
The prevalence of screening and HRT use are high in our
study population and we had the opportunity to examine
the respective effects of each of these factors on the change
in age of breast cancer occurrence. However, we realise
that our study has several shortcomings. Information on
HRT use was available only for approximately 50% of the
women diagnosed in the period 1997–2000. Although
these women were recruited in the context of a popula-
Invasive breast cancer incidence rates by age and period, Geneva cancer registry 1975–2003 Figure 1
Invasive breast cancer incidence rates by age and period, Geneva cancer registry 1975–2003.
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Invasive breast cancer incidence rates according to stage at diagnosis (panel a) and oestrogen receptor status (panel b) 1997– 2000 Figure 2
Invasive breast cancer incidence rates according to stage at diagnosis (panel a) and oestrogen receptor status (panel b) 1997–
2000. Panel a. Panel b.
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tion-based case-control study, they might not be com-
pletely representative of all breast cancer patients. We
compared them with the other 50–74 years old breast can-
cer patients recorded at the cancer registry and they
appeared to be similar in terms of age, social class, stage
distribution and tumour characteristics. Therefore, we
believe that selection bias does not explain the fact that
the new age distribution is only present among women
who used HRT, irrespective of their mammography
screening status. In addition, we have no information on
the duration of HRT utilisation, on HRT cessation, or on
time elapsed since the stop of HRT. It is therefore not pos-
sible to evaluate if the incidence peak occurred among
current or ex-users of HRT. Also, we were not able to eval-
uate incidence patterns according to type of HRT.
To our knowledge, only three studies have reported
important changes in age-specific breast cancer incidence
[14-16]. In Marin Country, Bay area, San Francisco, Prehn
et al. observed an increase in breast cancer incidence
among women aged 45–64 years for the period 1991–
1997, whereas the incidence among older and younger
women remained stable [14]. They ruled out screening
mammography as the most important reason, because the
incidence increase involved also advanced stages and lob-
ular cancers (which are difficult to detect mammographi-
cally), and because women aged 65–70 (an age-category
also covered by screening) showed no incidence increase.
The authors suggested HRT, frequently used by the rela-
tively wealthy, well-educated female population of this
area, as a possible explanation for the increasing breast
cancer incidence among women aged 45–64. It was in this
same region (Bay area) that the increase of endometrial
adenocarcinoma, associated with postmenopausal oestro-
gen use, was particularly high [17]. More recently, Hem-
minki et al. also reported an important change in age-
specific breast cancer incidence in Sweden [16]. They
observed a strong incidence increase among women aged
50–69 years, but only a slight decrease for women older
than 75 years. As this change in age-specific incidence
coincided with the introduction of organised mammogra-
phy screening programs, the authors attributed this inci-
dence pattern change to mammography screening.
Fuglede et al, reported on breast cancer incidence in a
population of unscreened women in Denmark from
1973–2002, using data of the nationwide Danish Cancer
Registry [15]. They showed that the age-specific incidence
rates of breast cancer increased throughout the whole
period. In addition, they observed marked changes in the
age-specific incidence pattern: between 1973–1981, there
Table 1: Patient and tumour characteristics by period of diagnosis among patients aged 60–64 years1
Patient and tumour characteristics 1975–1979 1985–1989 N = 218 (%) 1997–2000 2001–2003 N = 389 (%) P value for X2 of heterogeneity
Social class2
High 8 (6%) 72 (19%) P < 0.0000
Medium 57 (44%) 203 (52%)
Low 26 (20%) 53 (14%)
Unknown 39 (30%) 61 (16%)
Method of detection
Screening 31 (14%) 199 (51%) P < 0.0000
Other 187 (86%) 190 (49%)
Stage at diagnosis
I 69 (32%) 186 (48%) P < 0.0000
II 95 (44%) 149 (38%)
III and more 34 (16%) 42 (11%)
Unknown 20 (09%) 12 (3%)
Oestrogen 3 receptors
Positive 43 (61%) 311 (80%) P = 0.002
Negative 18 (25%) 53 (14%)
Unknown 10 (14%) 25 (6%)
Histological type
Ductal 173 (79%) 311 (80%) P < 0.0000
Lobular 4 (2%) 53 (14%)
Other 41 (19%) 25 (6%)
1) the age in which the incidence peak was observed after 1997
2) the first period concerned 1985–1989 as information on the woman's last occupation was available only after 1980;
3) the fist period concerned the years 1995–1996 as information on oestrogen receptor status was available only from 1995.BMC Cancer 2006, 6:78 http://www.biomedcentral.com/1471-2407/6/78
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was a plateau and change of slope around the age of 46–
48, which shifted to 64–66 years in 1994–2002. This was
not due to screening as they confined their study to a non-
screened population [15].
In our population, we believe that both HRT and, to a
lesser extent, mammography screening explain the change
in incidence pattern. Mammography screening advances
diagnosis by detecting breast cancer at an early pre-clinical
stage. This can explain why the change in pattern con-
cerned mainly the early stages. In this study however, we
did not observe the typical incidence peak among never
users of HRT with screen-detected tumours. In fact, only
ever users of HRT showed an incidence peak at 60–64
years, regardless whether the tumour was screen-detected
or not.
It has been suggested that HRT particularly increases the
risk of oestrogen receptor positive tumours [18]. In our
study, the changed incidence pattern involved only
women with oestrogen receptor positive tumours, which
supports our hypothesis of a potential effect of HRT use
on the change in age-specific breast cancer risk.
Recent studies showed that current users of HRT are at
increased risk of developing breast cancer [5, 19]. These
studies generally involved patients between 50–65 years
and the effect of ever use of HRT on breast cancer inci-
dence among elderly women (aged ≥ 75 years) has, to our
knowledge, never been examined.
Our results suggest that HRT use might not only increase
breast cancer risk among middle-aged women. It may also
bring forward the clinical appearance of breast cancer by
several years by stimulating the growth of oestrogen sen-
sible lesions and by inhibiting spontaneous slow down of
tumours when sex hormone levels drop during meno-
pause. This hypothesis is supported by a previous study,
which showed that postmenopausal women using HRT
were on average five years younger upon breast cancer
diagnosis than never users [20].
Use of HRT could have eliminated the temporary protec-
tive effect of menopausal oestrogen depletion.
Conclusion
The results of this study suggest that HRT may not only
increase the breast cancer risk among middle-aged
women, but that it may also bring forward the clinical
appearance of breast cancer. To get more insight in the
complex relationship between age-specific breast cancer
incidence, mammography screening and HRT, it could be
useful to perform international comparisons of cancer
registry data covering populations with different mam-
mography screening policies and different prevalences of
HRT use. The change in incidence pattern could have an
Invasive breast cancer incidence according to ever use of hormone replacement therapy (HRT) and detection by mammogra- phy screening, 1997–2000 Figure 3
Invasive breast cancer incidence according to ever use of hormone replacement therapy (HRT) and detection by mammogra-
phy screening, 1997–2000. As information on HRT use was available for 46% of all breast cancer patients, breast cancer inci-
dence rates are approximately half of the overall breast cancer incidence rates during the period 1997–2000.
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impact on breast cancer mortality. If the increase is "only"
anticipation in age at onset, we can expect that the subse-
quent mortality will remain stable. However, there is also
an anticipation of stage and that could lead to a future
lowered mortality. If it is a true increase in risk, then we
can expect a subsequent possible increase in mortality.
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